InspireMD (NYSEAMERICAN:NSPR) Trading Up 12.7%

InspireMD Inc (NYSEAMERICAN:NSPR)’s share price was up 12.7% during mid-day trading on Tuesday . The company traded as high as $3.58 and last traded at $3.28, approximately 295,885 shares traded hands during trading. An increase of 109% from the average daily volume of 141,776 shares. The stock had previously closed at $2.91.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of InspireMD in a research report on Monday, August 19th.

InspireMD (NYSEAMERICAN:NSPR) last announced its earnings results on Tuesday, August 6th. The medical equipment provider reported ($1.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.00) by $0.41. The company had revenue of $1.35 million for the quarter, compared to analyst estimates of $1.30 million.



A hedge fund recently bought a new stake in InspireMD stock. Bank of New York Mellon Corp purchased a new stake in shares of InspireMD Inc (NYSEAMERICAN:NSPR) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 23,946 shares of the medical equipment provider’s stock, valued at approximately $82,000. Bank of New York Mellon Corp owned approximately 1.76% of InspireMD at the end of the most recent quarter.

About InspireMD (NYSEAMERICAN:NSPR)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.

Featured Story: Why do commodities matter?

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.